Dr. Nardo, on his 1boringoldman blog, recaps his letter to the FDA concerning his findings after reviewing the research data on the new antidepressant Brintellix (Vortioxetine). “Takeda and Lundbeck had gone all out and to a lot of expense trying for this (cognitive boost) indication [6 cognition-specific clinical trials, bringing a lot of big KOL guns to the IOM workshop and earlier hearing, etc] . . . But it just wasn’t in the data, and that’s what the FDA is there to evaluate. So good on them. They did the right thing after all.”
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.